Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

View ORCID ProfileShuo Feng, Daniel J. Phillips, Thomas White, Homesh Sayal, View ORCID ProfileParvinder K. Aley, View ORCID ProfileSagida Bibi, View ORCID ProfileChristina Dold, View ORCID ProfileMichelle Fuskova, View ORCID ProfileSarah C. Gilbert, Ian Hirsch, View ORCID ProfileHolly E. Humphries, View ORCID ProfileBrett Jepson, Elizabeth J. Kelly, Emma Plested, Kathryn Shoemaker, Kelly M. Thomas, Johan Vekemans, Tonya L. Villafana, View ORCID ProfileTeresa Lambe, View ORCID ProfileAndrew J Pollard, View ORCID ProfileMerryn Voysey, the Oxford COVID Vaccine Trial Group
doi: https://doi.org/10.1101/2021.06.21.21258528
Shuo Feng
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shuo Feng
Daniel J. Phillips
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas White
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Homesh Sayal
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parvinder K. Aley
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Parvinder K. Aley
Sagida Bibi
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sagida Bibi
Christina Dold
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christina Dold
Michelle Fuskova
2NIHR Oxford Biomedical Centre, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michelle Fuskova
Sarah C. Gilbert
3The Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sarah C. Gilbert
Ian Hirsch
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Holly E. Humphries
5National Infection Service, Public Health England, Salisbury, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Holly E. Humphries
Brett Jepson
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brett Jepson
Elizabeth J. Kelly
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma Plested
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Shoemaker
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly M. Thomas
5National Infection Service, Public Health England, Salisbury, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Vekemans
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tonya L. Villafana
4AstraZeneca PLC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Lambe
3The Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Teresa Lambe
Andrew J Pollard
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
2NIHR Oxford Biomedical Centre, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrew J Pollard
Merryn Voysey
1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
2NIHR Oxford Biomedical Centre, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Merryn Voysey
  • For correspondence: merryn.voysey@paediatrics.ox.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Although 6 COVID-19 vaccines have been approved by the World Health Organisation as of 16th June 2021, global supply remains limited. An understanding of the immune response associated with protection could facilitate rapid licensure of new vaccines.

Methods Data from a randomised efficacy trial of ChAdOx1 nCoV-19 (AZD1222) vaccine in the UK was analysed to determine the antibody levels associated with protection against SARS-CoV-2. Anti-spike and anti-RBD IgG by multiplex immunoassay, pseudovirus and live neutralising antibody at 28 days after the second dose were measured in infected and non-infected vaccine recipients. Weighted generalised additive models for binary data were applied to symptomatic and asymptomatic SARS-CoV-2 infection data from ChAdOx1 nCoV-19 recipients. Cubic spline smoothed log antibody levels, and weights were applied to account for potential selection bias in sample processing. Models were adjusted for baseline risk of exposure to SARS-CoV-2 infection.

Results Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. Vaccine efficacy of 80% against primary symptomatic COVID-19 was achieved with an antibody level of 40923 (95% CI: 16748, 125017) and 63383 (95% CI: 16903, not computed (NC)) for anti-spike and anti-RBD, and 185 (95% CI: NC, NC) and 247 (95% CI: 101, NC) for pseudo- and live-neutralisation assays respectively. Antibody responses did not correlate with overall protection against asymptomatic infection.

Conclusions Correlates of protection can be used to bridge to new populations using validated assays. The data can be used to extrapolate efficacy estimates for new vaccines where large efficacy trials cannot be conducted. More work is needed to assess correlates for emerging variants.

Competing Interest Statement

Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. SCG is co-founder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1 vectored vaccines and a patent application covering this SARS-CoV-2 vaccine (PCT/GB2012/000467). TL is named as an inventor on a patent application covering this SARS-CoV-2 vaccine and was a consultant to Vaccitech for an unrelated project during the conduct of the study. AJP is chair of the UK Department of Health and Social Care (DHSC) Joint Committee on Vaccination & Immunisation (JCVI) but does not participate in discussions on COVID-19 vaccines, and is a member of WHO SAGE. AJP is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article do not necessarily represent the views of the DHSC JCVI NIHR or WHO. TW, HS, IH, JB, EJK, KS, JV, TLV are employees of AstraZeneca. The other authors declare no competing interests.

Clinical Trial

NCT04400838

Funding Statement

This Article reports independent research funded by UK Research and Innovation, Coalition for Epidemic Preparedness Innovations,the National Institute for Health Research, and AstraZeneca.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), reference 21584/0428/001 0001, and the South-Central Berkshire Research Ethics Committee, reference 20/SC/0179.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Anonymised participant data will be made available when the trial is complete, upon request directed to the corresponding author. Proposals will be reviewed and approved by the sponsor, investigator, and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement. All data will be made available for a minimum of 5 years from the end of the trial.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted June 24, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White, Homesh Sayal, Parvinder K. Aley, Sagida Bibi, Christina Dold, Michelle Fuskova, Sarah C. Gilbert, Ian Hirsch, Holly E. Humphries, Brett Jepson, Elizabeth J. Kelly, Emma Plested, Kathryn Shoemaker, Kelly M. Thomas, Johan Vekemans, Tonya L. Villafana, Teresa Lambe, Andrew J Pollard, Merryn Voysey, the Oxford COVID Vaccine Trial Group
medRxiv 2021.06.21.21258528; doi: https://doi.org/10.1101/2021.06.21.21258528
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng, Daniel J. Phillips, Thomas White, Homesh Sayal, Parvinder K. Aley, Sagida Bibi, Christina Dold, Michelle Fuskova, Sarah C. Gilbert, Ian Hirsch, Holly E. Humphries, Brett Jepson, Elizabeth J. Kelly, Emma Plested, Kathryn Shoemaker, Kelly M. Thomas, Johan Vekemans, Tonya L. Villafana, Teresa Lambe, Andrew J Pollard, Merryn Voysey, the Oxford COVID Vaccine Trial Group
medRxiv 2021.06.21.21258528; doi: https://doi.org/10.1101/2021.06.21.21258528

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (419)
  • Anesthesia (97)
  • Cardiovascular Medicine (894)
  • Dentistry and Oral Medicine (166)
  • Dermatology (101)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (404)
  • Epidemiology (8744)
  • Forensic Medicine (4)
  • Gastroenterology (403)
  • Genetic and Genomic Medicine (1844)
  • Geriatric Medicine (175)
  • Health Economics (386)
  • Health Informatics (1281)
  • Health Policy (642)
  • Health Systems and Quality Improvement (488)
  • Hematology (206)
  • HIV/AIDS (387)
  • Infectious Diseases (except HIV/AIDS) (10519)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (216)
  • Neurology (1744)
  • Nursing (100)
  • Nutrition (264)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (457)
  • Oncology (959)
  • Ophthalmology (279)
  • Orthopedics (107)
  • Otolaryngology (174)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (262)
  • Pediatrics (553)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1836)
  • Public and Global Health (3962)
  • Radiology and Imaging (649)
  • Rehabilitation Medicine and Physical Therapy (340)
  • Respiratory Medicine (532)
  • Rheumatology (214)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (165)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (105)
  • Urology (78)